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Abstract
Backgroud: Alzheimer disease is an age-related severe neu-
rodegenerative pathology. The level of the third endoge-
nous gas, hydrogen sulfide (H2S), is decreased in the brain of 
Alzheimer’s disease (AD) patients compared with the brain 
of the age-matched normal individuals; also, plasma H2S lev-
els are negatively correlated with the severity of AD. Recent-
ly, we have demonstrated that systemic H2S injections are 
neuroprotective in an early phase of preclinical AD. Objec-
tives: This study focuses on the possible neuroprotection of 
a chronic treatment with an H2S donor and sulfurous water 
(rich of H2S) in a severe transgenic 3×Tg-AD mice model. 
Method: 3×Tg-AD mice at 2 different ages (6 and 12 months) 
were daily treated intraperitoneally with an H2S donor and 
sulfurous water (rich of H2S) for 3 months consecutively. We 
investigated the cognitive ability, brain morphological alter-
ations, amyloid/tau cascade, excitotoxic, inflammatory and 
apoptotic responses. Results: Three months of treatments 
with H2S significantly protected against impairment in learn-
ing and memory in a severe 3×Tg-AD mice model, at both 
ages studied, and reduced the size of Amyloid β plaques 
with preservation of the morphological picture. This neuro-
protection appeared mainly in the cortex and hippocampus, 
associated with reduction in activity of c-jun N-terminal ki-
nases, extracellular signal-regulated kinases and p38, which 
have an established role not only in the phosphorylation of 
tau protein but also in the inflammatory and excitotoxic re-
sponse. Conclusion: Our findings indicate that appropriate 
treatments with various sources of H2S, might represent an 
innovative approach to counteract early and severe AD pro-
gression in humans. © 2018 S. Karger AG, Basel
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Introduction
Alzheimer’s disease (AD) is a severe, progressive and 
age-related neurodegenerative disorder that can be divid-
ed into a 3-stage model: early stage (characterized by mild 
AD: general forgetfulness) middle stage (moderate AD: 
forgetfulness, language and communication difficulty), 
and late stage (severe AD: inability to recognise familiar 
people and objects) [1]. Amyloid β (Aβ) accumulation in 
different areas of the brain, (as hippocampus and cortex, 
which are mainly involved in learning and memory) and 
tau hyperphosphorylation are the 2 main etiopathologi-
cal factors of AD, leading to an excitotoxic and inflamma-
tory response, with synaptic dysfunction, neurodegener-
ation, apoptotic death associated with neuronal loss and 
severe cognitive decline: this is the typical neurodegen-
eration process of AD [2–8]. The number of AD patients 
is constantly increasing. Indeed, according to estimates, 
40 million people worldwide have AD, and this number 
is expected to redouble by 2050 [9]. So, to find new effec-
tive therapies is the urgent need of the hour. 
Hydrogen sulfide (H2S) is best known as a highly tox-
ic, colourless and flammable gas, but recently it has been 
demonstrated that it is also the third endogenous gas, 
after nitric oxide and carbon monoxide, and all these gas-
es play important roles both in health and pathologic 
conditions [10]. The endogenous micromolar levels of 
H2S have been measured in the brain, blood and periph-
eral organs of rats, humans, and bovine and production 
differs considerably between the various mammalian 
species [11]; moreover, levels of H2S decrease with ageing 
[12]. Endogenous H2S is generated from cysteine metab-
olism through 2 enzymes: cystathionine-β-synthase and 
cystathionine-γ-lyase whose productions are mainly in 
the brain for the former and largely in the cardiovascular 
system for the latter [13, 14]. Growing evidence shows 
that H2S is an important signalling molecule in various 
body systems, and it gives beneficial effects in animal 
models of inflammation, hypertension, and ischemia/re-
perfusion injury inducing anti-inflammatory, cytopro-
tective, immunomodulating and trophic effects [10, 13–
18]. The relatively high endogenous concentrations of 
H2S in the brain suggest a neuromodulator role [19]; yet, 
to date, the detailed mechanisms involved have remained 
unknown. Furthermore, it has been reported that brain 
H2S synthesis is severely decreased in AD patients (up to 
55%) [20], and plasma H2S levels are negatively corre-
lated with the severity of AD [21]. Recently, it has been 
demonstrated that H2S donor sodium hydrosulfide re-
duces Aβ generation in cultured cells and subsequently, 
we have demonstrated this reduction also in vivo exper-
iments with improvement of cognitive performance in 
rats and transgenic mice with mild (early stage) AD [22].
This study focuses on the possible ability of a chronic 
treatment (3 months) with an H2S donor and a sulfurous 
water, with high content in H2S [23], to counteract the 
progression also in a severe (late stage) AD, at different 
ages (6 and 12 months). In particular, in a severe 3×Tg 
animal model of AD, we investigated cognitive ability, 
brain morphological alterations, amyloid/tau cascade, 
excitotoxic, inflammatory and apoptotic responses.
Materials and Methods
Animals
For this study, male 6 and 12 month-old (at the start of the 
study) 3×Tg-AD mice and their wild-type littermates (The Jackson 
Laboratories, Bar Harbor, ME, USA) were used. These mice har-
bour human transgenes APPSwe, PS1M146V and tauP301L overexpress 
mutant human APP, PS1 and tau protein respectively [22, 24]. An-
imals were kept in air-conditioned colony rooms (temperature 21 
± 1  ° C, humidity 60%) on a natural light/dark cycle (lights on at 
08: 00 am) with free access to food and water. Throughout the 
study, body weight was recorded. Animal sacrifice at the end of the 
study was performed under general anaesthesia with sodium pen-
tobarbital intraperitoneally (i.p.; Sigma-Aldrich, Milan, Italy). All 
experiments were carried out in strict accordance with the Euro-
pean Community guidelines governing animal welfare and protec-
tion for scientific purposes (CEE Council 89/609; Italian D.L. No. 
26, 2014) and approved by the Committee on Animal Health and 
Care of Modena and Reggio Emilia University. All efforts were 
made to minimize animal suffering and to reduce the number of 
animals used in this study. 
Drugs and Treatment Schedules
In this experimental model of severe AD, investigations with 
sodium hydrosulfide (NaHS), a H2S donor (Sigma-Aldrich, St. 
Louis, MO, USA) and sulfurous water (thermal-water with high 
H2S content; kindly provided by Salsomaggiore and Tabiano Ther-
mae, Tabiano, Italy) were carried out. Sulfurous water originates 
from Tabiano’s source Pergoli with the following characteristics: 
H2S level 125 mg/L (HS– 43 mg/L and not ionized H2S 82 mg/L), 
pH 6.6, osmolarity 41 mOsm/L [23]. Sulfurous water (12 mL/kg 
i.p.) and sodium hydrosulfide (0.5 mg/kg, i.p.) were administered 
once daily for 12 weeks starting at 6 or 12 months of age; therefore, 
mice were sacrificed at 9 and 15 months. Control animals (3×Tg-
AD mice and wild-type mice [WT]) received an equal volume of 
saline by the same route of administration. The doses of sodium 
hydrosulfide and sulfurous water, and time of animal sacrifice 
were chosen on the basis of our previous experiments [22]. The 
number of animals used for each group is indicated in figure leg-
ends.
Assessment of cognitive ability. As it is well known, Alzheimer 
disease is characterized by a progressive and severe cognitive de-
cline. For this reason, in the present study, the Morris water maze 
test was used to assess spatial learning and memory, as previously 
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described [6, 22, 25–27]. The apparatus consisted of a circular 
white pool at a fixed position (100 cm in diameter and 55 cm in 
height), filled to a depth of 15 cm with tap water (26 ± 1  ° C) made 
opaque with milk. A white, circular-shaped refuge platform of 
7 cm in diameter was submerged 1 cm below the water surface in 
one of the dials (target quadrant). The pool and the location of the 
platform were constant during all trials. 
Assess spatial learning. The spatial acquisition test was con-
ducted for 4 consecutive days and each day included one block of 
4 trials. Each trial began when mice were randomly placed into the 
pool with face at the wall of pool from one of the 4 starting point 
of a quadrant, and latency to find the hidden platform was record-
ed (escape latency). Each animal had a period of 60 s to locate the 
hidden platform, and when they detected the platform, they could 
stay on for 15 s, to allow the formation of a spatial map. Those mice 
not reaching the platform within 60 s were gently guided to the 
platform and allowed to rest for 15 s on it.
Probe test: To examine spatial reference memory, a probe 
test was administered 24 h after ending spatial acquisition. Dur-
ing the test, the platform was removed from the pool and the 
mouse started the test from the opposite dial with the face fac-
ing the pool wall and swims freely for 1 min [28]. The time 
spent and the number of crossings, in the quadrant where the 
platform was first placed (target zone), were recorded as spatial 
memory retention. 
Visible platform task. In order to evaluate the Visual-Motor co-
ordination of mice 1 h after the probe test, a visual cue test was 
conducted [28]. For this test, the platform was set 1 cm above the 
water level and marked with black tape so that the mice could lo-
cate the platform for musing a local visual stimulus rather than 
relying on spatial orientation to extra-maze cues. The platform was 
placed in the opposite of the target quadrant and the mouse was 
tested once beginning from the opposite quadrant of the platform. 
The time spent to reach the platform was recorded.
After the last behavioural session, animals were sacrificed and 
then histological, biochemical and biomolecular studies were per-
formed on their brain. 
Histology
These studies were carried out in the mice experimental mod-
els. At the end of the last behaviuoral test, transcardial perfusion 
with ice-cold 4% paraformaldehyde (phosphate-buffered) was 
performed; then animal brains were removed and processed for 
histologic examination, as previously described [25–27]. Hippo-
campus and cortex morphology were studied in 7-µm thick paraf-
fin-embedded sections, hematoxylin-eosin or Nissl method 
stained; the extent of Aβ plaques was assessed after ethanol-Congo 
red/Harris hematoxylin staining.
Morphological analyses were performed by using an Axiophot 
photomicroscope (Carl Zeiss, Jena, Germany), under ordinary and 
polarized light. Histometry was performed by using an image sys-
tem (analySIS, Soft Imaging System GmbH, Münster, Germany). 
Viable neurons in the CA1 subfield and cortex (neurons having 
granular cytoplasm and euchromatic nucleus with large nucleoli) 
and Aβ plaques were estimated in 5 randomly selected fields per 
slide and on 5 sections for each hippocampal sample. Aβ deposit 
extent was evaluated according to the following score scale of val-
ues: 0 = no detection, 1 = 0–100 µm2, 2 = 100–5,000 µm2, 3 = 
5,000–25,000 µm2, 4 = > 25,000 µm2. 
Isolation of Cytoplasmic Proteins and Western Blot Analysis
At the end of the last behaviuoral test, the whole hippocampus 
and cortex were dissected from the mouse brain and immediately 
frozen into liquid nitrogen and stored at –80  ° C. After the extrac-
tion of cytoplasmatic proteins (for analysis of phosphorylation 
state/level of APP, Tau, Aβ1–42, p-c-jun N-terminal kinases [JNK], 
p-extracellular signal-regulated kinases [ERK1/2] and p38) as pre-
viously described [6, 22, 25–27], proteins (40 μg for each sample) 
were denatured, electrophoretically separated and transferred 
onto nitrocellulose membranes. The staining of the blots with Pon-
ceau’s solution showed that total protein amount was equal in each 
lane. The blots were then blocked and incubated overnight at 4  ° C 
with the following primary antibodies: p-APP, phospho (p)-tau, 
p-tau Ser396, Aβ (1–42 specific), JNK 54/46, ERK1/2 44/42 and 
p-p38 (Cell Signaling, Charlottesville, VA, USA). The day after, the 
membranes were incubated with a specific secondary antibody 
peroxidase-conjugated for 1 h at room temperature. To prove 
equal loading, the blots were analysed for β-tubulin expression 
(house-keeping gene) using an anti- β-tubulin antibody (Cell Sig-
naling). The membranes were analysed by the enhanced chemilu-
minescence system according to the manufacturer’s protocol (Mil-
lipore). Protein signals were quantified by scanning densitometry 
using a bio-image analysis system (Bio-Profil, Celbio, Italy) and 
expressed as relative integrated intensity in comparison with those 
of normal (naïve) mice. The level of all bands was expressed as 
relative integrated intensity normalized versus β-tubulin (= 100) 
[6, 22, 25–27].
Statistical Analysis
All data were collected blinded to the treatment and are shown 
as mean ± SEM. Parametric data was analysed using SigmaPlot 
and Adobe Illustrator and SPSS17.0 software. The 2-way repeat-
ed measures ANOVA (behavioural data), or 1-way ANOVA (all 
other data), followed by the Student-Newman-Keuls’ test were 
used to detect the significance from different groups. Aβ deposit 
data was analysed by means of the Kruskal-Wallis test followed 
by the Mann-Whitney U-test. A value of p < 0.05 was considered 
significant.
Results
Sulfurous Water Improves Learning and Memory 
Performance in a Severe Transgenic Mouse Model of AD
WT, both 9 and 15 months, treated with saline, gave 
latencies to find the hidden platform continuously de-
creased during the 4 days of training (Fig. 1a, b).
3×Tg-AD mice, both 9 and 15 months, treated with sa-
line (controls) showed impaired ability (as compared with 
WT) in platform finding during all 4 days of behavioural 
test (Fig. 1a, b). Conversely, the 2 groups (9 and 15 months 
old) of transgenic mice treated with sulfurous water (12 
mL/kg i.p.) showed an improvement in spatial learning 
performance on the 4th day of training as compared with 
controls (Fig. 1a, b). Treatment with H2S donor, sodium 
hydrosulfide (0.5 mg/kg i.p.) did not significantly modify 
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the escape latency in 3×Tg-AD versus controls but showed 
only a trend to improve cognitive ability (Fig. 1a, b).
Twenty four hours after the Morris water test, animals 
were subjected to probe test. WT mice of both ages spent 
more time in quadrant where the platform was during the 
Morris test (original quadrant) respect to the 3×Tg-AD 
mice treated with saline (Fig. 1c, d), and also the number 
of crossings of this quadrant has been higher in WT mice 
respect to controls (Fig. 1e, f). 
Animals of 15 months treated with sulfurous water 
and with H2S donor sodium hydrosulfide showed both a 
significant enhancement of time spent in the original 
quadrant and a significant higher number of crossings 
with respect to control mice (Fig. 1d, f).
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Fig. 1. Donor of Sodium hydrosulfide and sulfurous water improve 
cognitive performance in 9- (a) and (b) 15-month old 3×Tg-AD. 
MWM was used to studied the learning performance, and was per-
formed in 9- and 15-month old mice (n = 12 and 8 mice per group, 
respectively). The MWM (4-day training) started at the beginning 
of the last week of treatment. The probe test was used to study the 
memory performance and was performed 24 h after the MWM 
test. Histograms’ height indicates mean values ± SEM of latency to 
escape onto the hidden platform (a, b), of time spent into the target 
zone (original quadrant; c, d) and number of crossings of the target 
zone (e, f). Sulfurous water (12 mL/kg i.p.) and donor of sodium 
hydrosulfide (0.5 mg/kg, i.p.) were administered once daily for 
12 weeks starting at 6 or 12 months of age.  * p < 0.05, at least, ver-
sus the corresponding value of 3×Tg mice treated with saline. WT, 
wild type; 3×Tg, 3×Tg-AD; S, saline; NaHS, donor of Sodium hy-
drosulfide; SW, sulfurous water.
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Motor activity. All mice after 1 h of probe test were 
placed in the pool with the platform visible to evaluate 
they ability to swim. All animals showed a similar time of 
escape latency and identical swimming speed in the Mor-
ris water maze compared with control mice (data not 
shown). 
Toxicity. No signs of toxicity were recorded through-
out the 3 months of treatment with sodium hydrosulfide 
or sulfurous water (e.g., ruffled fur, diarrhea, lethargy, ag-
gressiveness, hypothermia, alterations of spontaneous lo-
comotor exploration and grooming), and body weight 
variations throughout the study were similar in all exper-
imental groups (data not shown).
Sulfurous Water Preserves Hippocampus and  
Cortex Morphological Alterations in a Mice Model  
of AD at both Ages
To investigate the brain morphological features of AD 
in 9- and 15-months-old mice, we processed the hippo-
campus (data not shown) and cerebral cortex (Fig. 2; 2 
vulnerable regions of the AD brain) for histology. In both 
these areas and in both ages studied, in saline-treated 
3×Tg-AD mice we found a number of neurons showing 
irreversible (pyknosis, nuclear dust) or reversible (swol-
len perikaryon, cellular shrinkage) alterations (Fig. 2c, i), 
and this led to a significant decrease of viable neurons 
(Fig. 2a). Saline-treated 3xTg-AD mice showed, in both 
ages and areas, a substantial amyloid deposit compared 
with WT mice (Fig. 2b–d, h–l). 
On the contrary, treatments with sulfurous water sig-
nificantly preserved morphological picture, with a higher 
number of viable neurons (Fig. 2a, g), and a significant 
reduction in amyloid deposit in cortex (Fig. 2b, e, f, h, m, 
n) compared with 3×Tg-AD saline-treated mice. 
Treatments with sodium hydrosulfide did not signifi-
cantly preserve hippocampus and cortex morphological 
alterations (not shown).
Sulfurous Water and/or Donor Sodium Hydrosulfide 
Reduce APP, Aβ. Tau and MAPK Expression/Activity 
Level in 3×Tg-AD Mice
In the hippocampus and cortex, we also investigated, 
by western blot analysis, the main proteins of the amyloid 
cascade and tau proteins. In both examined areas (hip-
pocampus and cortex), at 9 and 15 months, 3×Tg-AD 
mice treated with saline showed a high phosphorylation 
level of APP activity (Fig. 3a, b) and high tau expression 
and tau activity phosphorylated at Ser396 (Fig. 3c, d), and 
treatment with sulfurous water and Na HS decreased sig-
nificantly these markers (Fig. 3a–e).
In 3×Tg-AD mice treated with saline, the expression 
of Aβ1–42 (Fig. 4a–c) was significantly higher, compared 
with WT, both hippocampus and cortex. Treatments 
with sulfurous water or NaHS, significant decreased the 
expression of Aβ1–42 (Fig. 4a–c). 
In neurodegenerative diseases, including AD, the 
MAPK play an important role in phosphorylation of tau 
protein [29]. It is well known that MAPK family members 
(JNK, p38 and ERK) are involved in the transcription reg-
ulation of several genes encoding for pro-inflammatory 
cytokines [29–30]. Our results showed, in the cortex and 
in the hippocampus of the saline-treated 3xTg-AD mice, 
at both age, an increase of activity of ERK (Fig. 5a, b), JNK 
(Fig. 5c, d) and P38 (Fig. 5f–g), as compared with WT 
mice. Treatment with sulfurous water or donor sodium 
hydrosulfide decreased significantly all these single 
MAPK (Fig. 5a–g). 
Discussion
Alzheimer’s disease is a multi-factor pathology be-
cause, not only neurology but also cardiology, ophthal-
mology and other medical specialties are involved in the 
study of its etiopathology and therapeutic approach [31–
33]. Indeed, in recent years, this broad spectrum of stud-
ies has led to demonstrate that endogenous H2S levels are 
decreased in the brains of patients and mice with AD [34, 
20]. This suggests that the restoration of H2S level could 
be a treatment for the Alzheimer’s disease. Indeed, our 
previous data showed that sub-chronic and chronic treat-
ments with H2S counteract the progression of early AD 
in rat and mouse models [22]. Herein, our present study 
demonstrates, for the first time, that sodium hydrosulfide 
(a donor of H2S) and sulfurous water (thermal-water rich 
of H2S content), administered for 3 months consecutive-
ly, preserve or slow down brain alterations and conse-
quent cognitive deficit, in a severe 3×Tg-AD mouse mod-
el. In these triplex transgenic 6-month-old mice, senile 
plagues began to appear, and after 9 months of age, the 
plagues of beta-amyloid are prominent with notable 
learning and memory impairments, inflammation, oxi-
dative stress and neuronal loss [22, 24]. All together, these 
symptoms represent a severe level of AD progression in 
3×Tg-AD mice. Our present results showed that the pres-
ervation or improvement in cognitive performance in-
duced by H2S’s treatments is associated with a trend of 
hippocampus and cortex reduction of Aβ deposits, low-
ered phosphorylation of APP and tau protein, and dimin-
ished morphological damage including a decreased neu-
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Fig. 2. Sulfurous water reduces histological damage and amyloid 
deposit in the cortex of 3×Tg mice at (a–f) 9- and (g–n) 15-month 
old. Histograms’ height indicates mean values ± SEM of the num-
ber of viable neurons (a, g) and of Aβ plaques extent (b, h). Groups 
of 9-month-old mice n = 12, and groups of 15-month-old mice n = 
8. c–f Representative histological pictures at 9 months of age: Aβ 
deposit in the sulfurous water-treated mouse both at ordinary (e) 
and polarized (F: birefringent image) light, compared with saline-
treated one (c, d). i–l Representative histological pictures at 15 
months of age: Aβ deposit in the sulfurous water-treated mouse 
both at ordinary (k) and polarized (N: birefringent image) light, 
compared with saline-treated one (i, j). Treatment is specified in 
the Figure 1. * p < 0.05, at least, versus the corresponding value of 
3×Tg mice treated with saline. Scale bar = 100 µm. WT, wild type; 
3xTg, 3xTg-AD; S, saline; SW, sulfurous water.
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Fig. 3. Sulfurous water and NaHS reduce APP and Tau expression/
activity in the hippocampus at 9 and 15 months (a–d) and in the 
cortex at 15 months (e) of 3×Tg-AD mice. Histograms’ height in-
dicates mean values ± SEM of p-APP and Tau. Groups of 9-month 
old mice n = 12, and groups of 15-month old mice n = 8. Treatment 
is specified in the Figure 1. The top of each panel shows represen-
tative immunoblots highlighting expression/activity of p-APP and 
of house-keeping gene product β-tubulin. * p < 0.05, at least, versus 
the corresponding value of 3xTg mice treated with saline. # p < 
0.05, at least, versus the corresponding value of wild type animals 
treated with saline. WT, wild-type mice WT; 3×Tg, 3×Tg-AD 
mice; S, saline; NaHS, donor of Sodium hydrosulfide; SW, sulfu-
rous water.
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ronal death in the CA1 subfield. It well known that the 2 
main events in AD pathophysiology are Aβ deposits and 
tau hyperphosphorylation and it has been demonstrated 
that Aβ and tau exert toxicity both with separate or merge 
mechanisms [22, 29, 30]. Indeed, in vitro and in vivo 
studies suggest that Aβ may lead to tau pathology, tau 
may mediate Aβ toxicity and together Aβ and tau may 
synergistically target different component of the same 
system [2, 29, 34]. In addition to the Aβ and tau-depen-
dent mechanisms, there are other several etiopathogenic 
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Fig. 4. Sulfurous water and NaHS reduce the Aβ1–42 expression 
in the hippocampus (a) and cortex (a, b) of 3×Tg-AD mice. His-
tograms’ height indicates mean values ± SEM of Aβ1–42 expres-
sion (n = 12 and 8 mice per group respectively). Groups of 
9-month-old mice n = 12, and groups of 15-month-old mice n = 
8. Treatment is specified in the Figure 1. The top of each panel 
shows representative immunoblots highlighting the expression of 
Aβ1–42 and of house-keeping gene product β-tubulin. * p < 0.05, 
at least, versus the corresponding value of 3×Tg mice treated with 
saline. # p < 0.05, at least, versus the corresponding value of wild 
type animals treated with saline. WT, wild-type mice; 3xTg, 3xTg-
AD mice; S, saline; NaHS, donor of Sodium hydrosulfide; SW, sul-
furous water.
Fig. 5. Sulfurous water and donor of sodium hydrosulfide reduce 
MAP-K (p-ERK, JNK and p-38) in the cortex (a–e) and in the hip-
pocampus (f, g) of 3×Tg-AD mice. Histograms’ height indicates 
mean values ± SEM of p-ERK, p-JNK and p-P38 activity. (n = 12 
and 8 mice per group, respectively). Groups of 9-month old mice 
n = 12, and groups of 15-month old mice n = 8. Treatment is spec-
ified in the Figure 1. The top of each panel shows representative 
immunoblots highlighting the activity of p-ERK, p-JNK, p-P38 
and of house-keeping gene product β-tubulin.* p < 0.05, at least, 
versus the corresponding value of 3xTg mice treated with saline. # p < 0.05, at least, versus the corresponding value of wild type 
animals treated with saline. WT, wild-type mice; 3×Tg, 3×Tg-AD 
mice; S, saline; NaHS, donor of Sodium hydrosulfide; SW, sulfu-
rous water.
(For figure 5a–g see next page.)
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mechanisms that could lead to AD, as apoptosis and in-
flammation [2, 6, 7, 22, 30]. Indeed, in this preclinical, 
transgenic AD study, we demonstrated, that, in a severe 
AD model, systemic chronic treatments with sulfurous-
water rich in H2S or NaHS induced an anti-inflammatory 
response, thereby reducing the activity of the MAPK 
members JNK, p38 and ERK, in the hippocampus and 
cortex at both ages considered. It is well known that 
MAPK members play an important role not only in in-
flammation but also in phosphorylation of tau protein. 
These biochemical and biomolecular results confirm im-
portant neuroprotective aspects of H2S, and demonstrate 
the ability to counteract the main established AD-related 
mechanisms of brain damage as inflammation. This anti-
inflammatory action of H2S on brain strengthens the 
well-known systemic anti-inflammatory response of H2S 
[35].
The identification of the sequence of events in the 
pathophysiology of AD is important for the novel identi-
fication of appropriate therapeutic approaches, leading to 
a series of potential therapies in AD because currently this 
sequence is still not well defined.
Several potential approaches for AD treatment such as 
cell and gene therapies are currently under investigation; 
however, a great number of compounds for AD failed to 
reach the goal [36]. 
One of the main aspects responsible for these failures 
of preclinical AD studies is that the compound under 
study affects only one of the pathophysiological respon-
sible for neurodegeneration of AD, or shows toxic side 
effects [3, 29, 37, 38]. For this reason AD remains a major 
cause of disability and mortality without an effective 
treatment.
Therefore, a winning strategy could be to identify sub-
stances able to affect simultaneously more pathophysio-
logical mechanisms of AD. Our present data shows that 
an H2S donor and/or sulfurous water with high H2S con-
tent, in a severe model of AD, improve cognitive activity 
by reducing Aβ deposits, hyperphosphorylation of APP 
and tau isoform at Ser396, as well as inflammatory re-
sponses. Noteworthy, the chronic treatment of 3 months 
did not show any evident signs of toxicity (perhaps a sign 
of toxicity could be glimpsed in the cortex of 15-month-
old animals treated with NaHS where beta-levels are 
higher than those of transgenic control animals). Again, 
our data are in agreement with a large number of evidence 
confirming that gaseous signalling molecule H2S exerts a 
cytoprotection in mammalian cells via multiple mecha-
nisms (modulation of ion channels, enzymes, transcrip-
tion factors and receptors) [10, 15, 16, 39–41]. For exam-
ple, there is evidence demonstrating that H2S is a phos-
phodiesterases inhibitor: in fact, levels of second 
messengers cAMP and cGMP increase [41]. Phosphodi-
esterases inhibition could be an early step leading to neu-
roprotective mechanisms induced by H2S also in our ex-
perimental condition, and our next goal is to exam spe-
cifically this aspect.
A restraint of this work is that we administered the 
substances by i.p. injection to standardize doses; our next 
aim will be to study these substances administered by oral 
and inhaled route, which are routes commonly used in 
humans for sulfurous waters. Furthermore, levels of H2S 
in plasma and brain are under investigation in our labo-
ratory, and will be the focus of our next paper.
In conclusion, our data supports the hypothesis that 
endogenous H2S might be physiologically involved in 
neuroprotection against AD and these positive results, 
obtained in a severe model of AD, should encourage fur-
ther studies to better define the potential therapeutic val-
ue of H2S alone or sulfurous waters with high H2S con-
tent. 
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